



Published in final edited form as:

Nat Rev Drug Discov. ; 11(1): 52–68. doi:10.1038/nrd3620.

## The Pharmacological Landscape and Therapeutic Potential of Serine Hydrolases

Daniel A. Bachovchin and Benjamin F. Cravatt

The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037

### Abstract

Serine hydrolases play critical roles in many biological processes, and several are targets of approved drugs for indications such as type 2 diabetes, Alzheimer's disease, and infectious disease. Despite this, most of the 200+ human serine hydrolases remain poorly characterized with respect to their physiological substrates and functions, and the vast majority lack selective, *in vivo*-active inhibitors. Here, we review the current state of pharmacology for mammalian serine hydrolases, including marketed drugs, compounds under clinical investigation, and selective inhibitors emerging from academic probe development efforts. We also highlight recent methodological advances that have accelerated the rate of inhibitor discovery and optimization for serine hydrolases, which we anticipate will aid in their biological characterization and, in some cases, therapeutic validation.

### Introduction

Serine hydrolases are one of the largest and most diverse classes of enzymes found in eukaryotes and prokaryotes. These enzymes, which include lipases, (thio)esterases, amidases, peptidases, and proteases, all utilize a base-activated serine nucleophile to cleave amide or (thio)ester bonds in substrates *via* a covalent acyl-enzyme intermediate (Fig. 1). In mammals, serine hydrolases represent ~1% of all proteins and play vital roles in many (patho)physiological processes, including blood clotting<sup>1</sup>, digestion<sup>2</sup>, nervous system signaling<sup>3</sup>, inflammation<sup>4</sup>, and cancer<sup>5–7</sup>. Serine hydrolases also perform critical functions in bacteria and viruses, where they contribute to pathogen life cycle<sup>8</sup>, virulence<sup>9</sup>, and drug resistance<sup>10</sup>.

The widespread biological significance of serine hydrolases has motivated many academic and industrial groups to develop inhibitors for enzymes from this class, both for use as chemical probes to study enzyme function and as potentially new therapeutic agents. Four general strategies have been successfully employed: 1) mining natural products (proteins, polysaccharides, and small-molecules), 2) converting endogenous substrates into inhibitors, 3) screening large compound libraries and optimizing lead scaffolds, and 4) tailoring compounds containing mechanism-based electrophiles, including carbamates<sup>11, 12</sup>, ureas<sup>13, 14</sup>, activated ketones<sup>15</sup>, and lactones/lactams<sup>16, 17</sup>, that covalently react with the active-site serine nucleophile. Although the last approach overlaps with the other strategies—e.g., electrophiles are intrinsic in some natural product scaffolds<sup>18, 19</sup> and have been extensively employed as “warheads” on enzyme substrates and/or products to convert them into inhibitors<sup>20, 21</sup>—screening of “hydrolase-directed” electrophile libraries broadly against serine hydrolases has emerged as a particularly fruitful independent approach for the identification of inhibitors<sup>11, 14</sup>. Together, these efforts have yielded a diverse array of

pharmacological tools, including proteins, peptides, polysaccharides, and small-molecules, that inhibit serine hydrolases with good selectivity, and several of these agents have been approved for clinical use to treat diseases such as type 2 diabetes, obesity, blood-clotting disorders, Alzheimer's disease, and bacterial and viral infections [Table 1 and Supplementary information S1 (table)].

Despite these advances, the vast majority of eukaryotic and prokaryotic serine hydrolases still lack selective inhibitors. Further, many serine hydrolases, including some that have been genetically linked to human disease, remain uncharacterized with respect to their physiologic substrates and functions. In this Review, we survey the current pharmacological toolkit and therapeutic potential for human serine hydrolases, giving special attention to modern chemoproteomic methods that have quickened the pace of inhibitor discovery and optimization. We also discuss the challenges that must be overcome to create selective inhibitors for the vast majority, if not all mammalian serine hydrolases, and highlight how they are being met by advances in screening and the development of classes of compounds that show preferential capacity to inactivate serine hydrolases.

## The human serine hydrolases

There are ~240 human serine hydrolases, which can be divided into two near-equal-sized subgroups – the serine proteases (~125 members) and the 'metabolic' serine hydrolases (~115 members) (Fig. 2).<sup>6</sup> The vast majority of serine proteases, which primarily cleave peptide bonds in proteins, have chymotrypsin-like or subtilisin-like folds (Fig. 2, black and red enzymes, respectively), with a catalytic serine nucleophile activated by participation in a catalytic triad with conserved histidine and aspartic acid residues.<sup>22</sup> Serine proteases typically exist as inactive precursors (i.e., zymogens), which are activated by limited proteolysis upon specific biological stimuli and subsequently inactivated by endogenous protein inhibitors.<sup>22, 23</sup> These enzymes include the well studied digestive protease trypsin and the critical blood clotting mediators thrombin and activated factor Xa (FXa).

The 'metabolic' serine hydrolases (Fig. 2) are comprised of a wide range of lipases, peptidases, esterases, thioesterases, and amidases that hydrolyze small-molecules, peptides, or post-translational (thio)ester protein modifications.<sup>6</sup> Consistent with their diverse substrate repertoire, the metabolic serine hydrolases are comprised of a much more structurally diverse group of enzymes than the serine proteases (Fig. 2, note branch length). The majority (>60%) of metabolic serine hydrolases have an  $\alpha/\beta$ -hydrolase fold and Ser-His-Asp catalytic triad, but this sub-family also includes several structurally and mechanistically distinct enzyme clades such as the patatin domain-containing lipases<sup>24</sup> and the amidase signature enzymes<sup>25, 26</sup>, which use Ser-Asp dyads and Ser-Ser-Lys triads for catalysis, respectively. Although several members of the metabolic serine hydrolase family have been extensively characterized, including acetylcholinesterase (ACHE), fatty acid amide hydrolase (FAAH), and dipeptidyl peptidase-4 (DPP-4), the majority are still unannotated with respect to their physiological substrates and functions.<sup>6</sup>

## Clinically approved inhibitors of human serine hydrolases

Small-molecule inhibitors have been clinically approved for six distinct human serine hydrolase targets, four of which are described below (Table 1). As several of these compounds are not perfectly selective for a single enzyme, and at least one, orlistat, is thought to derive therapeutic benefit from inhibiting several related enzymes<sup>27</sup>, the actual number of human serine hydrolases targeted by commercial drugs is likely higher than six. Interestingly, despite the pharmaceutical industry's perceived aversion to developing therapeutics that form covalent bonds with protein targets<sup>28</sup>, five of these drugs, rivastigmine<sup>29</sup>, saxagliptin<sup>30</sup>, vildagliptin<sup>31</sup>, orlistat<sup>32</sup>, and sivelestat<sup>33, 34</sup>, contain

electrophilic chemical groups that interact covalently with their target's active-site serine nucleophile. Additional examples of electrophilic drugs that target serine hydrolases include the  $\beta$ -lactam antibiotics<sup>35</sup>, which inhibit bacterial transpeptidase and  $\beta$ -lactamase enzymes, and the recently approved hepatitis C virus (HCV) drugs boceprevir and telaprevir<sup>36</sup>, which are  $\alpha$ -keto amides that inhibit the HCV NS3 protease [Supplementary information S1 (table)]. In addition to these small-molecule inhibitors, several large biomolecules and their derivatives (proteins, peptides, polysaccharides) that target serine hydrolases, such as thrombin, are either in clinical development or have been approved for clinical use<sup>37</sup>. However, due to space limitations, we will focus on small-molecule inhibitors of human serine hydrolases in this Review.

### Inhibitors of serine proteases involved in coagulation

Venous and arterial thromboembolic diseases, which are characterized by occlusion of blood vessels by thrombi (i.e., aggregations of platelets, fibrin, and cells), are a major cause of morbidity and mortality worldwide<sup>37</sup>. Several serine proteases play central roles in the blood coagulation pathway, where sequential activation of protease zymogens results in the rapid formation of insoluble fibrin blood clots<sup>1, 38</sup>, and have long been the main targets of anticoagulant drug development efforts. For the past half-century, heparins and vitamin K antagonists (e.g. warfarin), both of which indirectly inactivate several proteases in the cascade, have been the two major anticoagulant drug classes. However, these agents have important clinical drawbacks; heparins require parenteral administration due to their large size, and warfarin, although orally available, has a narrow therapeutic window, many food-drug interactions, and requires frequent monitoring<sup>37</sup>. More recent research efforts have focused on the development of selective and orally available small-molecules that directly block one of two key coagulation proteases, thrombin (also known as factor IIa) and activated factor Xa (FXa).

Thrombin, the final protease in the clotting cascade, cleaves fibrinogen into fibrin, potently activates platelets, and indirectly activates itself through a feedback loop<sup>39</sup>. Injectable direct thrombin inhibitors (DTIs) have been known for many years; the leech salivary peptide hirudin<sup>40</sup>, the hirudin-derivative bivalirudin<sup>41</sup>, and the small-molecule argatroban<sup>42</sup> (Table 1) are all clinically approved DTI anticoagulants<sup>43</sup>. The first orally available small-molecule DTI, ximelagatran (Exanta; AstraZeneca) was developed starting from a peptide scaffold that mimicked the thrombin substrate fibrinogen<sup>39</sup>. Ximelagatran, however, exhibited serious liver toxicity, and consequently was not approved in the United States and was withdrawn in Europe in 2006<sup>44</sup>. The next attempt to develop an orally available DTI originated from an X-ray crystal structure of the peptide-like inhibitor NAPAP in complex with bovine thrombin<sup>45</sup>. Replacement of the central NAPAP glycine residue with a more rigid isostere and subsequent optimization resulted in the reversible inhibitor dabigatran, which exhibited excellent anticoagulant activity in human blood with good selectivity for thrombin over related serine proteases<sup>46</sup>. However, dabigatran was not orally bioavailable, likely due to a highly basic amidine residue that was included to mimic the fibrinogen substrate. In order to achieve oral bioavailability, dabigatran was masked as a double prodrug (Table 1) (Dabigatran etexilate; Pradaxa; Boehringer Ingelheim), which is hydrolyzed to release dabigatran *in vivo*<sup>47</sup>. Importantly, dabigatran etexilate did not show any evidence of liver toxicity<sup>48</sup>, and has recently gained regulatory approval worldwide.

FXa, the other major protease target for anticoagulant development, cleaves prothrombin into active thrombin<sup>49</sup>. Potent parenteral FXa inhibitors have been known for decades, including the polypeptides antistasin<sup>50, 51</sup> and the tick anticoagulant peptide (TAP)<sup>52</sup>. These agents, together with more recently introduced pentasaccharide fondaparinux (Arixtra; GlaxoSmithKline)<sup>53</sup>, an analog of the heparin core that selectively inhibits FXa but not thrombin, were critical in elucidating the role of FXa in thrombosis and validating selective

FXa inhibition as a therapeutic strategy<sup>54</sup>. Initial small-molecule FXa inhibitors all contained amidine residues that served as prothrombin mimetics<sup>55, 56</sup>. As was observed with dabigatran, this highly basic group, although critical for potency, contributed to poor oral bioavailability<sup>57, 58</sup>. Bayer opted instead to screen a large (~200,000) library of compounds to identify a novel inhibitor scaffold<sup>59</sup>. From a lead with modest micromolar potency and structure-activity knowledge emanating from previous efforts, this team developed the highly potent, reversible FXa inhibitor rivaroxaban (Xarelto; Bayer HealthCare)<sup>54, 59</sup>. Rivaroxaban became the first selective small-molecule inhibitor of FXa approved for clinical use in 2008<sup>54</sup>. Several additional small-molecule inhibitors of both thrombin and FXa are currently in clinical development and have been recently reviewed<sup>60</sup>.

### Acetylcholinesterase inhibitors to treat Alzheimer's associated dementia

Acetylcholinesterase (ACHE) is a metabolic serine hydrolase that cleaves and inactivates the neurotransmitter acetylcholine<sup>61</sup>. More than 30 years ago, a decrease in cholinergic signaling was first observed in patients with Alzheimer's disease<sup>62–64</sup>, leading to the hypothesis that a loss in cholinergic neurotransmission contributed to the decline in cognitive function in these patients<sup>65</sup>. Consequently, it was proposed that increasing acetylcholine levels by inhibiting ACHE could alleviate symptoms of this disease. This premise has been validated clinically, and three ACHE inhibitors are currently used for the treatment of Alzheimer's associated dementia (Table 1). A fourth inhibitor, tacrine (Cognex; Shionogi), is approved but not recommended for use due to poor bioavailability and toxicity<sup>66</sup>. Essential to the successful use of these drugs is a graduated dosing regimen that avoids overt cholinergic toxicity<sup>67</sup>, such as that observed with large doses of organophosphorus nerve agents and insecticides that potently, but nonselectively inhibit ACHE<sup>68</sup>.

The three ACHE inhibitors in clinical use have notably different origins. Only one of these compounds, donepezil (Aricept; Eisai), is entirely synthetic, a result of derivatization of a scaffold identified from “blind” compound screening<sup>69</sup>. Donepezil reversibly inhibits ACHE, and has the highest selectivity (>1,000 fold) of the approved compounds for ACHE over the related serine hydrolase butyrylcholinesterase (BCHE)<sup>70, 71</sup>. Galantamine (Razadyne; Ortho-McNeil Janssen) is a natural product alkaloid first isolated in 1952 from the bulbs of the Caucasian snowdrop *Galanthus woronowi*<sup>72</sup>. Like donepezil, galantamine is a reversible inhibitor, but has a more modest 50-fold selectivity for ACHE over BCHE<sup>73, 74</sup>. The third approved compound, rivastigmine (Exelon; Novartis), is an optimized version of physostigmine, a natural product alkaloid with cholinergic activity<sup>75</sup>, with improved selectivity for the brain isoform of ACHE over peripheral ACHE and BCHE<sup>76</sup>. Rivastigmine, like physostigmine, contains an aryl carbamate group that acts as a slowly turned over ACHE substrate, effectively leading to the irreversible inactivation of the enzyme<sup>29</sup>. Following on the success of rivastigmine, carbamates have emerged as a versatile chemotype for serine hydrolase inhibitors, as embedding this tempered reactive group into various structural scaffolds has generated selective inhibitors for a diverse number of serine hydrolases<sup>11, 77, 78</sup>, as described in more detail below.

### Dipeptidyl peptidase 4 (DPP-4) inhibitors for type 2 diabetes

Dipeptidyl peptidase 4 (DPP-4) is a serine peptidase that cleaves N-terminal dipeptides from a variety of polypeptides that contain a proline or an alanine residue at the penultimate position<sup>79</sup>. Prominent among DPP-4 substrates are the incretins glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), which are released from the gut after food intake to promote insulin secretion and improve pancreatic  $\beta$  cell function<sup>80–84</sup>. Inhibition of DPP-4 prolongs the beneficial actions of GLP-1 and GIP, designating this enzyme as a therapeutic target for the treatment type 2 diabetes<sup>85</sup>.

Since 2007, five DPP-4 inhibitors have been approved for clinical use (Table 1), although vildagliptin<sup>31</sup> (Zomelis; Novartis) and alogliptin<sup>86</sup> (Nesina; Takeda) have not been approved in the United States. The earliest reported DPP-4 inhibitors were proline (or alanine)-based dipeptides (i.e., analogs of DPP-4 cleavage products) bearing chemical warheads, including boronic acids<sup>21</sup>, diphenyl phosphonates<sup>87</sup>, and nitriles<sup>20</sup>. Appropriately positioned nitrile groups, in particular, which form covalent reversible bonds with the serine nucleophile of DPP-4 to give high affinity binding<sup>30, 88, 89</sup>, resulted in selective and orally bioavailable compounds. These lead compounds were ultimately optimized to give vildagliptin<sup>31, 90</sup> and saxagliptin<sup>91, 92</sup> (Onglyza; Bristol Myers Squibb). Sitagliptin<sup>93</sup> (Januvia; Merck) and linagliptin<sup>94</sup> (Tradjenta; Boehringer Ingelheim), in contrast, were both optimized from novel structures—a  $\beta$ -amino acid scaffold<sup>95</sup> and xanthene-based scaffold<sup>94</sup>, respectively—identified from screening compound libraries. Finally, alogliptin emerged from medicinal chemistry efforts around a quinazolinone scaffold predicted to inhibit the active-site of DPP-4 by structure-based design<sup>86</sup>. Sitagliptin, linagliptin, and alogliptin inhibit DPP-4 through non-covalent, reversible mechanisms.

### Human serine hydrolases with emerging therapeutic potential

Many additional members of the serine hydrolase class have been implicated in disease, and inhibitors for several of these targets are in clinical development (Table 2). For example, fatty acid amide hydrolase (FAAH) inactivates a large class of amidated lipid transmitters, including the endogenous cannabinoid anandamide<sup>96</sup>. Genetic deletion or chemical inactivation of FAAH in rodents increases the levels of anandamide and related fatty acid amides to produce analgesia, anti-inflammation, anxiolysis, and anti-depression without the psychotropic side effects typically observed with direct cannabinoid receptor (CB1) agonists<sup>77, 97, 98</sup>. Recently, a high-throughput screen of the Pfizer chemical library uncovered a novel urea-containing FAAH inhibitor, which irreversibly inactivates the enzyme by covalently modifying FAAH's active-site serine<sup>99</sup>. The subsequent optimization of this scaffold resulted in the discovery of PF-04457845 (Table 2)<sup>13</sup>, a urea with exceptional selectivity for FAAH over other serine hydrolases and excellent pharmacokinetic properties in rats and dogs. The oral administration of PF-04457845 at 0.1 mg/kg exhibited similar antihyperalgesic effects as naproxen at 10 mg/kg in a rat model of inflammatory pain, and has since entered clinical trials.

A second example of an emerging drug target in the serine hydrolase class is PLA2G7 (or Lp-PLA2), a calcium-independent phospholipase A2 principally secreted by leukocytes and associated with circulating low density lipoprotein (LDL)<sup>100</sup>. Elevated levels of PLA2G7 were discovered to strongly correlate with an increased risk of coronary heart disease, suggesting a potential role for this enzyme in atherogenesis<sup>101</sup>. PLA2G7 can hydrolyze polar phospholipids in oxidized LDL to generate two key pro-inflammatory mediators, lysophosphatidylcholine (LPC) and oxidized nonesterified fatty acids (NEFAs)<sup>102, 103</sup>. LPC and oxidized NEFAs have been implicated in the development of atherosclerosis through several mechanisms, including homing of inflammatory cells and induction of apoptosis<sup>100</sup>. To investigate the biology and therapeutic potential of PLA2G7, GlaxoSmithKline optimized a selective, picomolar PLA2G7 inhibitor, darapladib (Table 2)<sup>104</sup>, from an initial micromolar HTS screening hit<sup>105</sup>. Darapladib blocked LPC and NEFA production in oxidized LDL<sup>103</sup> and significantly decreased coronary atherosclerotic plaque development in a diabetic and hypercholesterolemic swine model through an anti-inflammatory mechanism independent of cholesterol<sup>106</sup>. Darapladib is currently being evaluated in Phase III clinical trials.

More preliminary studies using gene knockouts, lead chemical inhibitors, and protein and gene expression profiling have implicated other serine hydrolases as being of potential therapeutic importance. For example, mice lacking prolylcarboxypeptidase (PRCP), which

cleaves C-terminal amino acids after proline in bioactive peptides, including angiotensin II and III<sup>107</sup>, have reduced body weight, food intake, and fat mass, designating PRCP as a potential target for obesity<sup>108</sup>. Merck has reported initial attempts to develop PRCP inhibitors<sup>109, 110</sup>, the first of which, 'compound 80' (Table 2), reversibly blocked PRCP activity with nanomolar potency and high selectivity over a panel of related serine peptidases<sup>109</sup>. Encouragingly, 'compound 80' significantly reduced food intake, body weight, and fat mass of wild-type mice compared with PRCP<sup>-/-</sup> mice. However, a recently reported second generation PRCP inhibitor reduced body weight and food intake similarly in wild-type and PRCP<sup>-/-</sup> mice<sup>110</sup>, indicating the effects, at least in this case, were independent of PRCP. The authors speculate that 'compound 80' may achieve higher levels of peripheral and/or central PRCP engagement than the second generation compound, and are currently pursuing more structurally diverse inhibitors with improved bioavailability to further evaluate this premise.

In addition, murine knockouts of three serine triglyceride (TG) hydrolases, triacylglycerol hydrolase (TGH), adipose triglyceride lipase (ATGL), and endothelial lipase (LIPG or EL), have implicated these enzymes as possible therapeutic targets for hypertriglyceridemia, cancer-associated cachexia, and cardiovascular disease, respectively. TGH, also referred to as carboxylesterase 3 (CES3) in mice and carboxylesterase 1 (CES1) in humans, can cleave TG stores in hepatocytes, which, after lipolysis, can serve as substrates for the assembly of apolipoprotein B (apoB)-containing very low-density lipoprotein (VLDL) particles<sup>111-113</sup>. Excitingly, TGH<sup>-/-</sup> mice have significantly decreased plasma triacylglycerol and apoB levels accompanied by improved insulin sensitivity and glucose tolerance<sup>114</sup>. GlaxoSmithKline has introduced the TGH inhibitor GR148672X (Table 2)<sup>115</sup>, but the selectivity, bioavailability, and molecular interactions of this compound with TGH have not been disclosed. ATGL, which can also mediate the lipolysis of stored TGs<sup>116</sup>, was recently evaluated for its role in an animal model of cancer-associated cachexia (CAC)<sup>117</sup>, a wasting syndrome characterized by the uncontrolled loss of muscle and adipose tissue. In this model, ATGL<sup>-/-</sup> mice resisted the loss of white adipose tissue and muscle mass observed in wild-type mice, suggesting ATGL inhibition could slow or stop CAC progression. However, to our knowledge ATGL inhibitors have not yet been reported. LIPG is an extracellular TG lipase that also possesses significant phospholipase activity<sup>118</sup>. LIPG<sup>-/-</sup> mice have increased high-density lipoprotein (HDL) levels compared to wild-type mice<sup>119, 120</sup>, whereas mice with transgenic overexpression of LIPG have significantly reduced HDL levels<sup>120</sup>. As HDL levels are inversely correlated with risk of cardiovascular disease, these genetic models strongly suggest that LIPG is a potential therapeutic target for this indication. GlaxoSmithKline has reported initial sulfonylfuran urea-based LIPG inhibitors (Table 2), but these compounds also inhibit the related enzyme lipoprotein lipase (LPL) and have not yet been evaluated *in vivo*<sup>121</sup>.

Another potential serine hydrolase drug target is prolyl endopeptidase (PREP), which is also referred to as prolyl oligopeptidase (POP). PREP is a post-proline cleaving enzyme that is highly expressed in the brain, kidney, and muscle, and testes<sup>122</sup>, and can degrade a variety of neuroactive peptides, including arginine-vasopressin (AVP), substance P, and thyrotropin-releasing hormone, among others<sup>123</sup>. As several of these substrates are involved in learning and memory, the inhibition of PREP has been suggested as a strategy for the treatment of cognitive defects associated with Alzheimer's disease, Parkinson's disease, and aging<sup>124</sup>. The majority of PREP inhibitor discovery efforts have centered around the modification of Z-prolyl-prolinal (ZPP), a peptide-based transition-state analog that competitively inhibits PREP<sup>125</sup>. Two compounds that emerged from this approach, JTP-4819<sup>126</sup> and the S 17092<sup>127</sup> (Table 2), inhibit PREP selectively over related peptidases and elevate the levels of several PREP peptide substrates in the brains of compound treated-animals<sup>126, 128-130</sup>. Encouragingly, the inhibition of PREP has been shown to produce gains

in cognitive function in aging rats<sup>131</sup> and in a chemically-induced model of early Parkinsonism in monkeys<sup>132</sup>. In humans, S 17092 showed preliminary evidence of eliciting improvements in a delayed memory task and in mood stabilization<sup>133, 134</sup>. Current work focused on the continued development of inhibitors with improved bioavailability and potency, combined with detailed mechanistic studies to molecularly understand the cognition enhancing effects of these compounds, should clarify the therapeutic potential of this target<sup>135</sup>.

Multiple serine hydrolases, such as fatty acid synthase (FASN)<sup>5</sup>, protein methylesterase-1 (PME-1)<sup>136</sup>, and the urokinase-type (uPA) and tissue-type (tPA) plasminogen activators<sup>137</sup>, have also been implicated in cancer<sup>138</sup>. Especially intriguing among potential cancer targets is fibroblast activation protein (FAP), the serine peptidase most homologous to DPP-4 (Fig. 2), which is highly expressed by stromal fibroblasts in most epithelial cancers<sup>139–141</sup>. Transfection of FAP in cancer cells promotes tumor growth in animals<sup>142</sup>. The nonselective dipeptide boronic acid FAP inhibitor PT-100 (Table 2) (Talabostat; Point Therapeutics) slowed tumor growth in mice, but PT-100's lack of specificity precludes assignment of the precise role of FAP inhibition in this model<sup>143, 144</sup>. A recent study demonstrated that removing the FAP<sup>+</sup> subpopulation of tumor stromal cells arrests the growth of solid tumors by inducing an immune response<sup>145</sup>. The pursuit of selective FAP inhibitors should further elucidate the role that this enzyme plays in tumorigenesis<sup>146, 147</sup>.

### Activity-based protein profiling for target discovery

As noted above, many serine hydrolases are regulated by post-translational mechanisms, which means that changes in their activity may not correlate well with their expression levels as measured by conventional proteomic<sup>148–151</sup> or genomic<sup>152, 153</sup> methods. This problem has been addressed by the development of a chemoproteomic technology termed activity-based protein profiling (ABPP)<sup>154, 155</sup>, which utilizes small-molecule probes to record changes in enzyme activity directly in native biological systems. An activity-based chemical probe typically contains at least two key features: 1) a reactive group that binds and covalently modifies the active sites of a large number of enzymes that share conserved mechanistic and/or structural features, and 2) a reporter tag (e.g., a fluorophore or biotin) to enable detection, enrichment, and identification of probe-labeled enzymes (Fig. 3a). Activity-based probes have been developed for numerous enzyme classes, including serine hydrolases<sup>156</sup>, cysteine-dependent enzymes<sup>157–159</sup>, kinases<sup>160</sup>, and histone deacetylases (HDACs)<sup>161, 162</sup>. Importantly, ABPP can be applied to any biological sample (cell line, tissue, or fluid) and coupled with either gel- or mass spectrometry (MS)-based readouts to characterize numerous enzyme activities in parallel<sup>155</sup>. The most commonly employed activity-based probes for serine hydrolases contain a fluorophosphonate (FP) reactive group that covalently reacts with the conserved serine nucleophile of these enzymes (Fig. 3b). A recent global analysis of tissue and cell line proteomes demonstrated that > 80% of mammalian metabolic serine hydrolases react with FP probes<sup>11</sup>. Although it is considerably more challenging to perform an equivalent survey of the serine proteases, which typically exist endogenously in their inactive zymogen or inhibitor-bound forms, many of these proteases have also been demonstrated react with FP-probes<sup>163–166</sup>.

ABPP has been applied to discover serine hydrolases that are involved a wide range of biological processes, including cancer<sup>138</sup>, nervous system signaling<sup>167</sup>, immune cell function<sup>168</sup>, obesity<sup>169, 170</sup>, and infectious disease<sup>171</sup>. For example, ABPP studies first identified AADACL1 as highly elevated in aggressive cancer cells<sup>172</sup>, where it functions as a 2-acetyl monoalkylglycerol ether (MAGE) hydrolase that controls the levels of the MAGE class of neutral ether lipids (NELs)<sup>173</sup>. Stable knockdown or chemical inhibition (with the carbamate inhibitors AS115 or JW480, Table 3) of AADACL1 in cancer cells reduces the levels of MAGEs and downstream bioactive lysophospholipids, ultimately impairing cancer

cell migration and invasion and in vivo tumor growth<sup>173, 174</sup>. In addition, monoacylglycerol lipase (MGLL), which can cleave a variety of monoglycerides into free fatty acids and glycerol, was similarly discovered to be highly elevated in aggressive cancer cells and primary tumors<sup>7</sup>, where it controls a free fatty acid (FFA) network that includes many oncogenic signaling lipids. Overexpression of MGLL in nonaggressive cancer cells promotes their pathogenicity, whereas knockdown or inhibition of MGLL with the selective inhibitor JZL184<sup>78</sup> (Table 3) impairs of tumor growth<sup>7, 175</sup>. In addition to its potential role in cancer, MGLL is responsible for the hydrolysis and inactivation of the endocannabinoid 2-arachidonoylglycerol (2AG), an endogenous ligand for the cannabinoid receptors CB1 and CB2. Acute MGLL inhibition with JZL184 results in CB1-dependent hypomotility and antinociception<sup>176, 177</sup>, suggesting MGLL inhibition could also be a therapeutic strategy for the treatment of pain. It should be noted that ABPP not only played an important role in discovery of AADACL1 and MGLL as therapeutic targets, but also that a competitive version of ABPP, described below, was instrumental in the development of AADACL1 and MGLL inhibitors. Moreover, ABPP analysis has recently shown that the retinoblastoma-binding protein 9 (RBBP9), which was initially discovered as a protein that could override TGF- $\beta$ -mediated antiproliferative signaling<sup>178</sup>, exhibits elevated activity in tumors and promotes anchorage-independent growth and pancreatic carcinogenesis<sup>179</sup>. Preliminary lead inhibitors for RBBP9 have been recently discovered using the high-throughput competitive ABPP strategies described below<sup>180, 181</sup>. Further research into other enzymes identified in ABPP studies, many of which remain poorly characterized, should yield insights into their basic biological functions and reveal whether they possess clinical relevance.

## Promising new strategies for inhibitor discovery

### Main challenges

Selective chemical inhibitors are notably lacking for the vast majority of human serine hydrolases, hindering investigations of their physiological roles and relationships to human disease. The dearth of inhibitors is likely due to at least three reasons: 1) many enzymes, in particular for those that are poorly characterized, lack suitable activity assays to enable compound screening, 2) achieving inhibitor selectivity for one enzyme is difficult amongst such a large, related protein family, and 3) compound libraries often do not contain tractable starting points for inhibitor optimization. Below, we discuss recently introduced approaches to address these challenges.

### Gel-based competitive ABPP

When applied in a competitive format that assays the ability of compounds to block probe labeling of enzymes, ABPP enables inhibitor discovery for enzymes independent of their degree of functional annotation<sup>15, 182, 183</sup>. Competitive ABPP traditionally involves incubation of a native proteome with a small-molecule, followed by labeling with a fluorescent activity-based probe, separation of proteins by SDS-PAGE, and quantification of the fluorescence intensity of probe-labeled enzymes relative to a control proteome (Fig. 3c; “gel-based competitive ABPP”).<sup>12, 15</sup> A complementary MS-based platform termed competitive ABPP-MudPIT has been introduced to further enhance the total protein coverage of these experiments<sup>12, 78</sup> (Fig. 3c). ABPP-MudPIT experiments require larger quantities of sample and more time than gel-based ABPP and are therefore typically reserved for more in-depth analysis of interesting lead inhibitors. In either gel or MS formats, a key advantage of competitive ABPP is that it permits simultaneous optimization of both the potency and selectivity of inhibitors against numerous related enzymes without requiring protein purification.



Gel-based competitive ABPP screening has enabled the discovery of selective inhibitors for many serine hydrolases (Table 3), including MGLL<sup>78</sup>, ABHD6<sup>11, 12</sup>, and FAAH<sup>15, 184</sup> (Table 2, OL-135). Key to the success of these efforts was the iterative optimization of compounds containing mechanism-based electrophiles, including carbamates, ureas, and activated ketones. Recently, to expand the number of enzyme-inhibitor interactions evaluated by competitive ABPP, a library of ~150 carbamates was screened against a representative 72-member panel of metabolic serine hydrolases<sup>11</sup>. Lead compounds were identified for numerous serine hydrolases, including currently pursued drug targets (e.g., PLA2G7, FAAH) and uncharacterized enzymes (e.g., ABHD11). Two compounds were subsequently optimized to create the first potent, selective, and *in vivo*-active inhibitors for the poorly characterized enzymes ABHD11<sup>11</sup> and AADACL1<sup>11, 174</sup>. Interestingly, this global analysis also identified several unanticipated pharmacological crosspoints within the serine hydrolase class, where two enzymes distantly related by sequence were found to share inhibitor sensitivity profiles. Such findings underscore the value of chemoproteomic methods like competitive ABPP that can assess compound selectivity broadly across an entire enzyme class. Some clades of enzymes (e.g., the dipeptidyl peptidases), however, were not inhibited by any of the tested carbamates, indicating that additional chemotypes may be necessary to successfully target most/all subsets of serine hydrolases. Consistent with this premise, competitive ABPP analysis of a library of triazole ureas recently identified selective inhibitors for enzymes that were insensitive to carbamates, including platelet-activating factor acetylhydrolase-2 (PAFAH2) and acyl-peptide hydrolase (APEH) (Table 3)<sup>14</sup>.

Competitive ABPP was also employed to assess the selectivity of the urea FAAH inhibitor PF-04457845 before this compound entered clinical trials<sup>13</sup>. PF-04457845, as well as other urea inhibitors of FAAH<sup>185</sup>, irreversibly inactivate this enzyme by carbamylating its serine nucleophile. Even though there are many irreversibly acting drugs on the market today, the pharmaceutical industry tends to prefer non-covalent, reversible inhibitors in large part due to concerns that irreversible inhibitors will lack specificity for a single protein target<sup>28</sup>. This concern, however, can be directly addressed by competitive ABPP and related chemoproteomic methods<sup>186</sup>, and when these approaches were applied to urea inhibitors of FAAH, such as PF-04457845, the compounds were found to be extremely selective for FAAH relative to serine hydrolases (and the rest of the proteome)<sup>13, 185</sup>. Once such a high degree of selectivity has been established for irreversible inhibitors, their distinctive advantages over reversibly acting compounds can be highlighted, namely that they can often inactivate their protein targets at very low doses (and with suboptimal pharmacokinetic properties) *in vivo*<sup>28, 186, 187</sup>. Moreover, the enzyme itself serves as a biomarker for compound activity in that *in vivo* inhibition can be experimentally verified by ABPP of cell, tissue, or fluid proteomes from compound-treated animals<sup>78</sup>.

### High-throughput screening by competitive ABPP

Competitive ABPP has traditionally been limited by throughput, as only a few hundred compounds can be reasonably screened by gel-based methods. To overcome this barrier, a high-throughput version of competitive ABPP has recently been introduced where the interaction between an activity-based probe and an enzyme is monitored by fluorescence polarization (fluopol-ABPP)<sup>180</sup> (Fig. 4). Fluopol-ABPP has been successfully applied to numerous enzymes from multiple mechanistic classes<sup>181, 188, 189</sup>, including several serine hydrolases. In one example, protein methylesterase-1 (PME-1), a serine hydrolase that removes an unusual post-translational carboxymethylation from the C-terminus of PP2A<sup>190</sup> and has been implicated in Alzheimer's disease<sup>191</sup> and cancer<sup>136</sup>, was screened against the NIH-300,000+ small-molecule library<sup>189, 192</sup>. This effort uncovered an aza- $\beta$ -lactam inhibitor (ABL127; Table 3) that selectively and covalently inhibits PME-1 with nanomolar

potency. ABL127, without any medicinal chemistry optimization, showed excellent activity in living cells and mice, where it selectively inhibited PME-1 relative other serine hydrolases and decreased the levels of demethylated PP2A. Interestingly, ABL127 originated from an academic contribution to the NIH library from a synthetic chemistry laboratory exploring the substrate scope of a chiral catalyst<sup>193</sup>. That ABL127 was contributed to the NIH library without any specific protein target in mind underscores the potential of academic chemistry, when paired with high-throughput screening, to serve as a driving force for the discovery of new bioactive chemotypes and chemical probes.

### Substrate activity screening

Even though competitive ABPP platforms address several critical challenges in serine hydrolase inhibitor discovery, many enzymes still do not have lead inhibitors, perhaps due to the absence of suitable lead compounds in chemical libraries. This deficiency should be met, at least in part, by the introduction and exploration of new hydrolase-directed chemotypes, as described above. In a complementary strategy, Ellman and coworkers introduced a technique called ‘substrate activity screening’ (SAS). This method involves the screening of a diverse library of *N*-acyl aminocoumarins, which fluoresce when cleaved, to identify initial, weak-binding enzyme substrates<sup>194</sup>. After a substrate is optimized for improved binding, the cleaved bond can then be replaced with a mechanism-based pharmacophore to convert it directly into an inhibitor. Although SAS has been successfully applied to select cysteine<sup>194, 195</sup> and serine (chymotrypsin)<sup>196</sup> proteases, it requires some intrinsic activity on at least one member *N*-acyl aminocoumarin library, which not all serine hydrolases will likely possess. One potential future direction could involve the creation of an even more diverse *N*-acyl aminocoumarin compound library for initial substrate screening. Alternatively, poor enzyme substrates, including those without any intrinsic fluorescence, can also be identified by other methods, for example by appearing as weak inhibitors in competitive ABPP experiments<sup>181</sup>. These substrates could potentially be converted into effective inhibitors *via* the introduction of appropriate chemical warheads in a similar manner.

### Serine traps as ‘tethers’ for starting point discovery

Electrophilic traps, regardless of their inherent capacity for enzyme selectivity and/or bioavailability, can also be employed as ‘tethers’ to enable the initial identification and optimization of lead compound scaffolds that would otherwise be too weak-binding to detect. For example, Merck researchers screened a library of  $\alpha$ -keto heterocycles, a chemotype well known to inhibit serine hydrolases<sup>15, 197</sup>, to achieve a starting point for the development of PRCP inhibitors<sup>109</sup>. After some compound optimization, the  $\alpha$ -keto heterocycle group was replaced with an isostere to improve the selectivity for PRCP over related enzymes, avoid potential bioavailability liabilities due to the ketone moiety, and facilitate derivative synthesis. Similarly, an electrophilic ketone was used in the early stages in the development of ximeligatran<sup>39</sup>. We should note that a conceptually analogous strategy, called “tethering”, which involves the engineering of a cysteine residue into a protein (or utilizing a native cysteine, if one exists) that can capture weak-binding, disulfide-containing compounds, has shown promise for the identification of starting points for ligand development for several protein classes<sup>198, 199</sup>, and could also prove useful for the discovery of serine hydrolase inhibitors.

### Engineering of biologics

While the inhibition of intracellular serine hydrolases is still the exclusive domain of small-molecules, some extracellular serine hydrolases may also be targeted by large macromolecules (e.g., hirudin and TAP). Encouragingly, the engineering of such macromolecular protease inhibitors has already been successful in improving existing and

uncovering novel pharmacological tools<sup>41, 200</sup>. For example, Craik and coworkers used phage display to optimize the *E. coli* protein ecotin, which naturally inhibits several trypsin-fold proteases, for selective inhibition of plasma kallikrein<sup>201</sup>. Similarly, Kunitz domain-containing proteins have been modified for selective blockade of plasma kallikrein<sup>200</sup> and tissue factor-factor VIIa (TF-FVIIa)<sup>202</sup>. In addition to natural protein scaffolds with intrinsic protease inhibitor activity, antibodies have been elicited to selectively block the activity of certain serine proteases<sup>203–205</sup>. One advantage such protein scaffolds offer is the ability to inhibit regions of the protein outside of the enzyme active-site, which are traditionally challenging to bind with small-molecules<sup>205</sup>.

## Conclusions

Serine hydrolases have already yielded numerous targets of marketed drugs to treat a wide array of human diseases. Given this precedent, it is tantalizing to extrapolate that many additional drug targets may be found among the numerous enzymes from this class that remain poorly characterized. Achieving this goal, however, will require much more extensive efforts to elucidate the biochemical and physiological roles, as well as disease-relevance for serine hydrolases. Here, we believe that the development of selective and *in vivo*-active inhibitors is critical. Indeed, many serine hydrolases play complex roles in mammalian physiology that cannot easily be modeled in cell culture experiments. Consider, for instance, the regulation of the GLP-1 incretin by DPP-4 or the termination of cholinergic and endocannabinoid signaling in the nervous system by ACHE and FAAH, respectively. These pathways, and likely many others regulated by serine hydrolases, require the integrated physiology of an intact animal for their characterization.

So far, *in vivo*-active inhibitors are available for only a handful of serine hydrolases. While it might be tempting to prioritize, based on current biological knowledge, enzymes from the class for future inhibitor development efforts, we would urge against this inclination. As has been nicely delineated in a recent Perspective by Edwards and colleagues, there appears to be a strong correlation between the volume of research activity (and biological understanding) on a particular protein and the availability of high-quality chemical tools to probe this protein's function<sup>206</sup>. This type of meta-analysis suggests that the creation of inhibitors often *precedes and drives* our biological understanding of enzymes, rather than the other way around, and argues for the development of inhibitors for all enzymes, regardless of their current perceived biological and/or therapeutic importance.

Encouragingly, inhibitors emerging from competitive ABPP span the full range of serine hydrolases to include enzymes that are biologically characterized and those that are devoid of functional annotation. Continued efforts following the inhibitor discovery strategies described in this Review, in particular, high-throughput screening of compound libraries and diversification of mechanism-based electrophiles, show particular promise, in our mind, to deliver new chemical probes for serine hydrolases. We also believe that further expansion of the NIH small-molecule library with structurally diverse compounds, like the aza- $\beta$ -lactams, should provide useful new starting points for drug development, as well as an exciting opportunity for academic synthetic chemists. While achieving the ultimate goal of developing a selective and *in vivo*-active inhibitor for every mammalian serine hydrolase (as well as critical serine hydrolases in important human pathogens) may seem far away, we believe that it can be accomplished. The resulting pharmacopeia would not only power biological discovery, but also serve as a starting point for next-generation therapeutics for the betterment of human health.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank the Cravatt laboratory for helpful discussions. This work was supported by the National Institutes of Health (DA025285, GM090294, CA132630, DA017259, DA009789, and CA087660), the National Science Foundation (predoctoral fellowship to D.A.B.), the California Breast Cancer Research Program (predoctoral fellowship to D.A.B.), and The Skaggs Institute for Chemical Biology.

## References

1. Davie EW, Ratnoff OD. Waterfall Sequence for Intrinsic Blood Clotting. *Science*. 1964; 145:1310–2. [PubMed: 14173416]
2. Whitcomb DC, Lowe ME. Human pancreatic digestive enzymes. *Dig Dis Sci*. 2007; 52 :1–17. [PubMed: 17205399]
3. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. *Int J Neuropsychopharmacol*. 2006; 9:101–24. [PubMed: 16083515]
4. Bonventre JV, et al. Reduced fertility and postischemic brain injury in mice deficient in cytosolic phospholipase A2. *Nature*. 1997; 390:622–5. [PubMed: 9403693]
5. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nat Rev Cancer*. 2007; 7:763–77. [PubMed: 17882277]
6. Simon GM, Cravatt BF. Activity-based proteomics of enzyme superfamilies: serine hydrolases as a case study. *Journal of Biological Chemistry*. 2010; 285:11051–5. [PubMed: 20147750]
7. Nomura DK, et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. *Cell*. 2010; 140:49–61. [PubMed: 20079333]
8. Steuber H, Hilgenfeld R. Recent advances in targeting viral proteases for the discovery of novel antivirals. *Curr Top Med Chem*. 10:323–45. [PubMed: 20166951]
9. White MJ, et al. The HtrA-like serine protease PepD interacts with and modulates the Mycobacterium tuberculosis 35-kDa antigen outer envelope protein. *PLoS One*. 6:e18175. [PubMed: 21445360]
10. Damblon C, et al. The catalytic mechanism of beta-lactamases: NMR titration of an active-site lysine residue of the TEM-1 enzyme. *Proc Natl Acad Sci U S A*. 1996; 93:1747–52. [PubMed: 8700829]
11. Bachovchin DA, et al. Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. *Proc Natl Acad Sci U S A*. 2010; 107:20941–6. [PubMed: 21084632]
12. Li W, Blankman JL, Cravatt BF. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. *J Am Chem Soc*. 2007; 129:9594–5. [PubMed: 17629278]
13. Johnson DS, et al. Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. *ACS Med Chem Lett*. 2011; 2:91–96. [PubMed: 21666860]
14. Adibekian A, et al. Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors. *Nat Chem Biol*. 2011
15. Leung D, Hardouin C, Boger DL, Cravatt BF. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. *Nat Biotechnol*. 2003; 21:687–91. [PubMed: 12740587]
16. Hoover HS, Blankman JL, Niessen S, Cravatt BF. Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. *Bioorg Med Chem Lett*. 2008; 18:5838–41. [PubMed: 18657971]
17. Tew DG, Boyd HF, Ashman S, Theobald C, Leach CA. Mechanism of inhibition of LDL phospholipase A2 by monocyclic-beta-lactams. Burst kinetics and the effect of stereochemistry. *Biochemistry*. 1998; 37:10087–93. [PubMed: 9665713]
18. Stedman E, Barger GJ. Physostigmine (eserine). Part III. *J Chem Soc*. 1925; 127:247–258.

19. Weibel EK, Hadvary P, Hochuli E, Kupfer E, Lengsfeld H. Lipstatin, an inhibitor of pancreatic lipase, produced by *Streptomyces toxytricini*. I. Producing organism, fermentation, isolation and biological activity. *J Antibiot (Tokyo)*. 1987; 40:1081–5. [PubMed: 3680018]
20. Li J, Wilk E, Wilk S. Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26). *Arch Biochem Biophys*. 1995; 323:148–54. [PubMed: 7487060]
21. Flentke GR, et al. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. *Proc Natl Acad Sci U S A*. 1991; 88:1556–9. [PubMed: 1671716]
22. Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. *Protein Sci*. 1995; 4:337–60. [PubMed: 7795518]
23. Yousef GM, Kopolovic AD, Elliott MB, Diamandis EP. Genomic overview of serine proteases. *Biochem Biophys Res Commun*. 2003; 305:28–36. [PubMed: 12732192]
24. Kienesberger PC, Oberer M, Lass A, Zechner R. Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions. *J Lipid Res*. 2009; 50 (Suppl):S63–8. [PubMed: 19029121]
25. Shin S, et al. Structure of malonamidase E2 reveals a novel Ser-cisSer-Lys catalytic triad in a new serine hydrolase fold that is prevalent in nature. *EMBO J*. 2002; 21:2509–16. [PubMed: 12032064]
26. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. *Science*. 2002; 298:1793–6. [PubMed: 12459591]
27. Shi Y, Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. *Nat Rev Drug Discov*. 2004; 3:695–710. [PubMed: 15286736]
28. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. *Nat Rev Drug Discov*. 10:307–17. [PubMed: 21455239]
29. Bar-On P, et al. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. *Biochemistry*. 2002; 41:3555–64. [PubMed: 11888271]
30. Metzler WJ, et al. Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation. *Protein Sci*. 2008; 17:240–50. [PubMed: 18227430]
31. Villhauer EB, et al. 1-[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. *J Med Chem*. 2003; 46:2774–89. [PubMed: 12801240]
32. Hadvary P, Sidler W, Meister W, Vetter W, Wolfer H. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. *J Biol Chem*. 1991; 266:2021–7. [PubMed: 1899234]
33. Kawabata K, et al. ONO-5046, a novel inhibitor of human neutrophil elastase. *Biochem Biophys Res Commun*. 1991; 177:814–20. [PubMed: 2049103]
34. Nakayama Y, et al. Clarification of mechanism of human sputum elastase inhibition by a new inhibitor, ONO-5046, using electrospray ionization mass spectrometry. *Bioorg Med Chem Lett*. 2002; 12:2349–53. [PubMed: 12161131]
35. Silver LL. Multi-targeting by monotherapeutic antibacterials. *Nat Rev Drug Discov*. 2007; 6:41–55. [PubMed: 17159922]
36. Flores MV, Strawbridge J, Ciaramella G, Corbau R. HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism. *Biochim Biophys Acta*. 2009; 1794:1441–8. [PubMed: 19505593]
37. Mackman N. Triggers, targets and treatments for thrombosis. *Nature*. 2008; 451:914–8. [PubMed: 18288180]
38. Macfarlane RG. An Enzyme Cascade in the Blood Clotting Mechanism, and Its Function as a Biochemical Amplifier. *Nature*. 1964; 202:498–9. [PubMed: 14167839]
39. Gustafsson D, et al. A new oral anticoagulant: the 50-year challenge. *Nat Rev Drug Discov*. 2004; 3:649–59. [PubMed: 15286732]
40. Markwardt F. The development of hirudin as an antithrombotic drug. *Thromb Res*. 1994; 74:1–23. [PubMed: 8029805]

41. White HD, Chew DP. Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions. *Expert Opin Pharmacother.* 2002; 3:777–88. [PubMed: 12036417]
42. Okamoto S. A synthetic thrombin inhibitor taking extremely active stereostructure. *Thromb Haemost.* 1979; 42:A205.
43. Walenga JM. An overview of the direct thrombin inhibitor argatroban. *Pathophysiol Haemost Thromb.* 2002; 32 (Suppl 3):9–14. [PubMed: 12811006]
44. Boudes PF. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. *Contemp Clin Trials.* 2006; 27 :432–40. [PubMed: 16769255]
45. Brandstetter H, et al. Refined 2.3 Å X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. *J Mol Biol.* 1992; 226:1085–99. [PubMed: 1518046]
46. Huel NH, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. *J Med Chem.* 2002; 45:1757–66. [PubMed: 11960487]
47. Eisert WG, et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. *Arterioscler Thromb Vasc Biol.* 2010; 30:1885–9. [PubMed: 20671233]
48. Schulman S, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med.* 2009; 361:2342–52. [PubMed: 19966341]
49. Fujikawa K, Legaz ME, Kato H, Davie EW. The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent). *Biochemistry.* 1974; 13:4508–16. [PubMed: 4473201]
50. Nutt E, et al. The amino acid sequence of antistasin. A potent inhibitor of factor Xa reveals a repeated internal structure. *J Biol Chem.* 1988; 263:10162–7. [PubMed: 3164720]
51. Tuszynski GP, Gasic TB, Gasic GJ. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. *J Biol Chem.* 1987; 262:9718–23. [PubMed: 3689495]
52. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. *Science.* 1990; 248:593–6. [PubMed: 2333510]
53. Bauer KA, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. *Cardiovasc Drug Rev.* 2002; 20 :37–52. [PubMed: 12070533]
54. Perzborn E, Roehrig S, Straub A, Kubitzka D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. *Nat Rev Drug Discov.* 2011; 10 :61–75. [PubMed: 21164526]
55. Becker RC, Alexander J, Dyke CK, Harrington RA. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. *Thromb Haemost.* 2004; 92 :1182–93. [PubMed: 15583722]
56. Sato K, et al. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. *Eur J Pharmacol.* 1997; 339:141–6. [PubMed: 9473127]
57. Lam PY, et al. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. *J Med Chem.* 2003; 46 :4405–18. [PubMed: 14521405]
58. Pinto DJ, et al. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4 -yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. *J Med Chem.* 2001; 44:566–78. [PubMed: 11170646]
59. Roehrig S, et al. Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methylthiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. *J Med Chem.* 2005; 48:5900–8. [PubMed: 16161994]
60. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. *Annu Rev Med.* 2011; 62:41–57. [PubMed: 21226611]
61. Giacobini E. Cholinesterases: New roles in brain function and in Alzheimer's disease. *Neurochemical Research.* 2003; 28:515–522. [PubMed: 12675140]
62. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. *Brain.* 1976; 99:459–96. [PubMed: 11871]

63. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. *Lancet*. 1976; 2:1403. [PubMed: 63862]
64. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. *J Neurol Sci*. 1977; 34:247–65. [PubMed: 144789]
65. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. *Science*. 1982; 217:408–14. [PubMed: 7046051]
66. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T. Drug class review on Alzheimer's drugs: final report. *Drug Class Reviews*. 2006
67. Ellis JM. Cholinesterase inhibitors in the treatment of dementia. *J Am Osteopath Assoc*. 2005; 105:145–58. [PubMed: 15863734]
68. Casida JE, Quistad GB. Serine hydrolase targets of organophosphorus toxicants. *Chem Biol Interact*. 2005; 157–158:277–83.
69. Kawakami Y, et al. The rationale for E2020 as a potent acetylcholinesterase inhibitor. *Bioorg Med Chem*. 1996; 4:1429–46. [PubMed: 8894101]
70. Nochi S, Asakawa N, Sato T. Kinetic-Study on the Inhibition of Acetylcholinesterase by 1-Benzyl-4-[(5,6-Dimethoxy-L-Indanon)-2-Yl]Methylpiperidine Hydrochloride (E2020). *Biological & Pharmaceutical Bulletin*. 1995; 18:1145–1147. [PubMed: 8535413]
71. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. *J Med Chem*. 1995; 38:4821–9. [PubMed: 7490731]
72. Harvey AL. The pharmacology of galanthamine and its analogues. *Pharmacol Ther*. 1995; 68:113–28. [PubMed: 8604434]
73. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. *Life Sci*. 1990; 46:1553–8. [PubMed: 2355800]
74. Thomsen T, Bickel U, Fischer JP, Kewitz H. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. *Eur J Clin Pharmacol*. 1990; 39:603–5. [PubMed: 2095347]
75. Hemsworth BA, West GB. The anticholinesterase activity of physostigmine. *J Pharm Pharmacol*. 1968; 20:406–7. [PubMed: 4385453]
76. Kennedy JS, et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. *J Clin Psychopharmacol*. 1999; 19:513–21. [PubMed: 10587286]
77. Kathuria S, et al. Modulation of anxiety through blockade of anandamide hydrolysis. *Nat Med*. 2003; 9:76–81. [PubMed: 12461523]
78. Long JZ, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. *Nat Chem Biol*. 2009; 5:37–44. [PubMed: 19029917]
79. Bongers J, Lambros T, Ahmad M, Heimer EP. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. *Biochim Biophys Acta*. 1992; 1122:147–53. [PubMed: 1353684]
80. Rosenblum JS, Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. *Curr Opin Chem Biol*. 2003; 7:496–504. [PubMed: 12941425]
81. Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. *Endocr Rev*. 2006; 27:719–27. [PubMed: 17077190]
82. Thorens B. Glucagon-like peptide-1 and control of insulin secretion. *Diabete Metab*. 1995; 21:311–8. [PubMed: 8586147]
83. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. *Regul Pept*. 2002; 107:1–13. [PubMed: 12137960]
84. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. *Gastroenterology*. 2002; 122:531–44. [PubMed: 11832466]
85. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. *Diabetes*. 1998; 47:1663–70. [PubMed: 9792533]
86. Feng J, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. *J Med Chem*. 2007; 50:2297–300. [PubMed: 17441705]

87. Lambeir AM, et al. Dipeptide-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl peptidase IV. *Biochim Biophys Acta*. 1996; 1290:76–82. [PubMed: 8645710]
88. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine], a slow-binding inhibitor of dipeptidyl peptidase IV. *Biochemistry*. 1999; 38:11597–603. [PubMed: 10512614]
89. Oefner C, et al. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[[[2-[(5-iodopyridin-2-yl)amino]ethyl]amino]-acetyl]-2-cyano-(S)-pyrrolidine. *Acta Crystallogr D Biol Crystallogr*. 2003; 59:1206–12. [PubMed: 12832764]
90. Villhauer EB, et al. 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. *J Med Chem*. 2002; 45:2362–5. [PubMed: 12036346]
91. Magnin DR, et al. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-L-cis-4,5-methanoprolinenitrile-based inhibitors. *J Med Chem*. 2004; 47:2587–98. [PubMed: 15115400]
92. Augeri DJ, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. *J Med Chem*. 2005; 48:5025–37. [PubMed: 16033281]
93. Kim D, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. *J Med Chem*. 2005; 48:141–51. [PubMed: 15634008]
94. Eckhardt M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. *J Med Chem*. 2007; 50:6450–3. [PubMed: 18052023]
95. Xu J, et al. Discovery of potent and selective beta-homophenylalanine based dipeptidyl peptidase IV inhibitors. *Bioorg Med Chem Lett*. 2004; 14:4759–62. [PubMed: 15324903]
96. Cravatt BF, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. *Nature*. 1996; 384:83–7. [PubMed: 8900284]
97. Naidu PS, et al. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. *Psychopharmacology*. 2007; 192:61–70. [PubMed: 17279376]
98. Cravatt BF, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. *Proceedings of the National Academy of Sciences of the United States of America*. 2001; 98:9371–6. [PubMed: 11470906]
99. Ahn K, et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. *Biochemistry*. 2007; 46:13019–30. [PubMed: 17949010]
100. Zalewski A, Macphee C, Nelson JJ. Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis. *Curr Drug Targets Cardiovasc Haematol Disord*. 2005; 5:527–32. [PubMed: 16503872]
101. Packard CJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. *N Engl J Med*. 2000; 343:1148–55. [PubMed: 11036120]
102. MacPhee CH, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. *Biochem J*. 1999; 338 ( Pt 2):479–87. [PubMed: 10024526]
103. Davis B, et al. Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. *J Biol Chem*. 2008; 283:6428–37. [PubMed: 18165686]
104. Blackie JA, et al. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. *Bioorg Med Chem Lett*. 2003; 13:1067–70. [PubMed: 12643913]
105. Boyd HF, et al. 2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2. *Bioorg Med Chem Lett*. 2000; 10:395–8. [PubMed: 10714508]




106. Wilensky RL, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. *Nat Med.* 2008; 14:1059–66. [PubMed: 18806801]
107. Mallela J, Yang J, Shariat-Madar Z. Prolylcarboxypeptidase: a cardioprotective enzyme. *Int J Biochem Cell Biol.* 2009; 41:477–81. [PubMed: 18396440]
108. Wallingford N, et al. Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. *J Clin Invest.* 2009; 119:2291–303. [PubMed: 19620781]
109. Zhou C, et al. Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity. *J Med Chem.* 2010; 53:7251–63. [PubMed: 20857914]
110. Shen HC, et al. Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors. *Bioorg Med Chem Lett.* 2011; 21:1299–305. [PubMed: 21315588]
111. Lehner R, Verger R. Purification and characterization of a porcine liver microsomal triacylglycerol hydrolase. *Biochemistry.* 1997; 36:1861–8. [PubMed: 9048571]
112. Lehner R, Vance DE. Cloning and expression of a cDNA encoding a hepatic microsomal lipase that mobilizes stored triacylglycerol. *Biochem J.* 1999; 343(Pt 1):1–10. [PubMed: 10493905]
113. Dolinsky VW, Gilham D, Alam M, Vance DE, Lehner R. Triacylglycerol hydrolase: role in intracellular lipid metabolism. *Cell Mol Life Sci.* 2004; 61:1633–51. [PubMed: 15224187]
114. Wei E, et al. Loss of TGH/Ces3 in mice decreases blood lipids, improves glucose tolerance, and increases energy expenditure. *Cell Metab.* 2010; 11:183–93. [PubMed: 20197051]
115. Gilham D, et al. Inhibitors of hepatic microsomal triacylglycerol hydrolase decrease very low density lipoprotein secretion. *FASEB J.* 2003; 17:1685–7. [PubMed: 12958176]
116. Zechner R, Kienesberger PC, Haemmerle G, Zimmermann R, Lass A. Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. *J Lipid Res.* 2009; 50 :3–21. [PubMed: 18952573]
117. Das SK, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. *Science.* 2011; 333:233–8. [PubMed: 21680814]
118. McCoy MG, et al. Characterization of the lipolytic activity of endothelial lipase. *J Lipid Res.* 2002; 43:921–9. [PubMed: 12032167]
119. Ma K, et al. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. *Proc Natl Acad Sci U S A.* 2003; 100:2748–53. [PubMed: 12601178]
120. Ishida T, et al. Endothelial lipase is a major determinant of HDL level. *J Clin Invest.* 2003; 111:347–55. [PubMed: 12569160]
121. Goodman KB, et al. Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. *Bioorg Med Chem Lett.* 2009; 19:27–30. [PubMed: 19058966]
122. Kato T, Okada M, Nagatsu T. Distribution of post-proline cleaving enzyme in human brain and the peripheral tissues. *Mol Cell Biochem.* 1980; 32:117–21. [PubMed: 7007867]
123. Wilk S. Prolyl endopeptidase. *Life Sci.* 1983; 33:2149–57. [PubMed: 6358755]
124. Lopez A, Tarrago T, Giralt E. Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010. *Expert Opin Ther Pat.* 21:1023–44. [PubMed: 21539473]
125. Bakker AV, Jung S, Spencer RW, Vinick FJ, Faraci WS. Slow tight-binding inhibition of prolyl endopeptidase by benzyloxycarbonyl-prolyl-prolinal. *Biochem J.* 1990; 271:559–62. [PubMed: 2241932]
126. Toide K, Iwamoto Y, Fujiwara T, Abe H. JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. *J Pharmacol Exp Ther.* 1995; 274:1370–8. [PubMed: 7562510]
127. Barelli H, et al. S 17092–1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. *Biochem Biophys Res Commun.* 1999; 257:657–61. [PubMed: 10208839]
128. Bellemere G, Morain P, Vaudry H, Jegou S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. *J Neurochem.* 2003; 84:919–29. [PubMed: 12603817]
129. Nolte WM, Tagore DM, Lane WS, Saghatelian A. Peptidomics of prolyl endopeptidase in the central nervous system. *Biochemistry.* 2009; 48:11971–81. [PubMed: 19911840]

130. Toide K, et al. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain. *Naunyn Schmiedebergs Arch Pharmacol.* 1996; 353:355–62. [PubMed: 8692293]
131. Shinoda M, Okamiya K, Toide K. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on thyrotropin-releasing hormone-like immunoreactivity in the cerebral cortex and hippocampus of aged rats. *Jpn J Pharmacol.* 1995; 69:273–6. [PubMed: 8699636]
132. Schneider JS, Giardiniere M, Morain P. Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys. *Neuropsychopharmacology.* 2002; 26:176–82. [PubMed: 11790513]
133. Morain P, et al. S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. *CNS Drug Rev.* 2002; 8:31–52. [PubMed: 12070525]
134. Morain P, Boeijinga PH, Demazieres A, De Nanteuil G, Luthringer R. Psychotropic profile of S 17092, a prolyl endopeptidase inhibitor, using quantitative EEG in young healthy volunteers. *Neuropsychobiology.* 2007; 55:176–83. [PubMed: 17700042]
135. Lambeir AM. Translational research on prolyl oligopeptidase inhibitors: the long road ahead. *Expert Opin Ther Pat.* 21:977–81. [PubMed: 21679099]
136. Puustinen P, et al. PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. *Cancer Res.* 2009; 69:2870–7. [PubMed: 19293187]
137. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. *Cell Mol Life Sci.* 2000; 57:25–40. [PubMed: 10949579]
138. Nomura DK, Dix MM, Cravatt BF. Activity-based protein profiling for biochemical pathway discovery in cancer. *Nat Rev Cancer.* 2010; 10:630–8. [PubMed: 20703252]
139. Scanlan MJ, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. *Proc Natl Acad Sci U S A.* 1994; 91:5657–61. [PubMed: 7911242]
140. Rettig WJ, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. *Cancer Res.* 1993; 53:3327–35. [PubMed: 8391923]
141. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. *Proc Natl Acad Sci U S A.* 1990; 87:7235–9. [PubMed: 2402505]
142. Cheng JD, et al. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. *Cancer Res.* 2002; 62:4767–72. [PubMed: 12183436]
143. Cheng JD, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. *Mol Cancer Ther.* 2005; 4:351–60. [PubMed: 15767544]
144. Adams S, et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. *Cancer Res.* 2004; 64:5471–80. [PubMed: 15289357]
145. Kraman M, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. *Science.* 2010; 330:827–30. [PubMed: 21051638]
146. Edosada CY, et al. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. *J Biol Chem.* 2006; 281:7437–44. [PubMed: 16410248]
147. Wolf BB, Quan C, Tran T, Wiesmann C, Sutherlin D. On the edge of validation--cancer protease fibroblast activation protein. *Mini Rev Med Chem.* 2008; 8:719–27. [PubMed: 18537727]
148. Patterson SD, Aebersold RH. Proteomics: the first decade and beyond. *Nat Genet.* 2003; 33 (Suppl):311–23. [PubMed: 12610541]
149. Yates JR 3rd. Mass spectral analysis in proteomics. *Annu Rev Biophys Biomol Struct.* 2004; 33:297–316. [PubMed: 15139815]
150. Domon B, Aebersold R. Mass spectrometry and protein analysis. *Science.* 2006; 312:212–7. [PubMed: 16614208]
151. Cravatt BF, Simon GM, Yates JR 3rd. The biological impact of mass-spectrometry-based proteomics. *Nature.* 2007; 450:991–1000. [PubMed: 18075578]

152. Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science*. 1999; 286:531–7. [PubMed: 10521349]
153. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. *Nat Genet*. 1999; 21:33–7. [PubMed: 9915498]
154. Evans MJ, Cravatt BF. Mechanism-based profiling of enzyme families. *Chem Rev*. 2006; 106:3279–301. [PubMed: 16895328]
155. Cravatt BF, Wright AT, Kozarich JW. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. *Annu Rev Biochem*. 2008; 77:383–414. [PubMed: 18366325]
156. Liu Y, Patricelli MP, Cravatt BF. Activity-based protein profiling: the serine hydrolases. *Proc Natl Acad Sci U S A*. 1999; 96:14694–9. [PubMed: 10611275]
157. Weerapana E, Simon GM, Cravatt BF. Disparate proteome reactivity profiles of carbon electrophiles. *Nat Chem Biol*. 2008; 4:405–7. [PubMed: 18488014]
158. Kato D, et al. Activity-based probes that target diverse cysteine protease families. *Nat Chem Biol*. 2005; 1:33–8. [PubMed: 16407991]
159. Weerapana E, et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. *Nature*. 2010; 468:790–5. [PubMed: 21085121]
160. Patricelli MP, et al. Functional interrogation of the kinome using nucleotide acyl phosphates. *Biochemistry*. 2007; 46:350–8. [PubMed: 17209545]
161. Salisbury CM, Cravatt BF. Activity-based probes for proteomic profiling of histone deacetylase complexes. *Proc Natl Acad Sci U S A*. 2007; 104:1171–6. [PubMed: 17227860]
162. Salisbury CM, Cravatt BF. Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. *J Am Chem Soc*. 2008; 130:2184–94. [PubMed: 18217751]
163. Madsen MA, Deryugina EI, Niessen S, Cravatt BF, Quigley JP. Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation. *J Biol Chem*. 2006; 281:15997–6005. [PubMed: 16611636]
164. Pan Z, et al. Development of activity-based probes for trypsin-family serine proteases. *Bioorg Med Chem Lett*. 2006; 16:2882–5. [PubMed: 16554154]
165. Jessani N, et al. Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. *Proc Natl Acad Sci U S A*. 2004; 101:13756–61. [PubMed: 15356343]
166. Jessani N, et al. A streamlined platform for high-content functional proteomics of primary human specimens. *Nat Methods*. 2005; 2:691–7. [PubMed: 16118640]
167. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. *Chem Biol*. 2007; 14:1347–56. [PubMed: 18096503]
168. Mahrus S, Craik CS. Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. *Chem Biol*. 2005; 12:567–77. [PubMed: 15911377]
169. Barglow KT, Cravatt BF. Discovering disease-associated enzymes by proteome reactivity profiling. *Chem Biol*. 2004; 11:1523–31. [PubMed: 15556003]
170. Morak M, et al. Differential activity-based gel electrophoresis for comparative analysis of lipolytic and esterolytic activities. *J Lipid Res*. 2009; 50:1281–92. [PubMed: 19282273]
171. Kaschani F, et al. Diversity of serine hydrolase activities of unchallenged and botrytis-infected *Arabidopsis thaliana*. *Mol Cell Proteomics*. 2009; 8:1082–93. [PubMed: 19136719]
172. Jessani N, Liu Y, Humphrey M, Cravatt BF. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. *Proc Natl Acad Sci U S A*. 2002; 99:10335–40. [PubMed: 12149457]
173. Chiang KP, Niessen S, Saghatelian A, Cravatt BF. An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. *Chem Biol*. 2006; 13:1041–50. [PubMed: 17052608]
174. Chang JW, Nomura DK, Cravatt BF. A Potent and Selective Inhibitor of KIAA1363/AADACL1 that Impairs Prostate Cancer Pathogenesis. *Chem Biol*. 2011; 18:476–84. [PubMed: 21513884]


175. Nomura DK, et al. Monoacylglycerol Lipase Exerts Dual Control over Endocannabinoid and Fatty Acid Pathways to Support Prostate Cancer. *Chem Biol.* 2011; 18:846–56. [PubMed: 21802006]
176. Long JZ, Nomura DK, Cravatt BF. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. *Chem Biol.* 2009; 16:744–53. [PubMed: 19635411]
177. Kinsey SG, et al. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. *J Pharmacol Exp Ther.* 2009; 330:902–10. [PubMed: 19502530]
178. Woitach JT, Zhang M, Niu CH, Thorgeirsson SS. A retinoblastoma-binding protein that affects cell-cycle control and confers transforming ability. *Nat Genet.* 1998; 19:371–4. [PubMed: 9697699]
179. Shields DJ, et al. RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia. *Proc Natl Acad Sci U S A.* 2010; 107:2189–94. [PubMed: 20080647]
180. Bachovchin DA, Brown SJ, Rosen H, Cravatt BF. Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes. *Nat Biotechnol.* 2009; 27:387–94. [PubMed: 19329999]
181. Bachovchin DA, et al. Oxime esters as selective, covalent inhibitors of the serine hydrolase retinoblastoma-binding protein 9 (RBBP9). *Bioorg Med Chem Lett.* 2010; 20:2254–8. [PubMed: 20207142]
182. Kidd D, Liu Y, Cravatt BF. Profiling serine hydrolase activities in complex proteomes. *Biochemistry.* 2001; 40:4005–4015. [PubMed: 11300781]
183. Greenbaum D, et al. Chemical approaches for functionally probing the proteome. *Mol Cell Proteomics.* 2002; 1:60–68. [PubMed: 12096141]
184. Lichtman AH, et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. *J Pharmacol Exp Ther.* 2004; 311:441–8. [PubMed: 15229230]
185. Ahn K, et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. *Chem Biol.* 2009; 16:411–20. [PubMed: 19389627]
186. Johnson DS, Weerapana E, Cravatt BF. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. *Future Med Chem.* 2010; 2:949–964. [PubMed: 20640225]
187. Potashman MH, Duggan ME. Covalent modifiers: an orthogonal approach to drug design. *J Med Chem.* 2009; 52:1231–46. [PubMed: 19203292]
188. Knuckley B, et al. A fluopol-ABPP HTS assay to identify PAD inhibitors. *Chem Commun (Camb).* 2010; 46:7175–7. [PubMed: 20740228]
189. Bachovchin DA, et al. Organic Synthesis Toward Small-Molecule Probes and Drugs Special Feature: Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methyltransferase-1 inhibitors. *Proc Natl Acad Sci U S A.* 2011; 108:6811–6. [PubMed: 21398589]
190. Lee J, Chen Y, Tolstykh T, Stock J. A specific protein carboxyl methyltransferase that demethylates phosphoprotein phosphatase 2A in bovine brain. *Proc Natl Acad Sci U S A.* 1996; 93:6043–7. [PubMed: 8650216]
191. Sontag JM, Numbhakdi-Craig V, Mitterhuber M, Ogris E, Sontag E. Regulation of protein phosphatase 2A methylation by LCMT1 and PME-1 plays a critical role in differentiation of neuroblastoma cells. *J Neurochem.* 2010; 115:1455–65. [PubMed: 21044074]
192. Bachovchin DA, et al. Discovery and Optimization of Sulfonyl Acrylonitriles as Selective, Covalent Inhibitors of Protein Phosphatase Methyltransferase-1. *J Med Chem.* 2011
193. Berlin JM, Fu GC. Enantioselective nucleophilic catalysis: the synthesis of aza-beta-lactams through [2+2] cycloadditions of ketenes with azo compounds. *Angew Chem Int Ed Engl.* 2008; 47:7048–50. [PubMed: 18668500]
194. Wood WJ, Patterson AW, Tsuruoka H, Jain RK, Ellman JA. Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. *J Am Chem Soc.* 2005; 127:15521–7. [PubMed: 16262416]
195. Patterson AW, et al. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method. *J Med Chem.* 2006; 49:6298–307. [PubMed: 17034136]

196. Salisbury CM, Ellman JA. Rapid identification of potent nonpeptidic serine protease inhibitors. *Chembiochem*. 2006; 7:1034–7. [PubMed: 16708409]
197. Edwards PD, Zottola MA, Davis M, Williams J, Tuthill PA. Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl alpha-ketobenzoxazoles. *J Med Chem*. 1995; 38:3972–82. [PubMed: 7562931]
198. Erlanson DA, et al. Site-directed ligand discovery. *Proc Natl Acad Sci U S A*. 2000; 97:9367–72. [PubMed: 10944209]
199. Erlanson DA, Wells JA, Braisted AC. Tethering: fragment-based drug discovery. *Annu Rev Biophys Biomol Struct*. 2004; 33:199–223. [PubMed: 15139811]
200. Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. *Expert Opin Investig Drugs*. 2006; 15:1077–90.
201. Stoop AA, Craik CS. Engineering of a macromolecular scaffold to develop specific protease inhibitors. *Nat Biotechnol*. 2003; 21:1063–8. [PubMed: 12923547]
202. Dennis MS, Lazarus RA. Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection. *J Biol Chem*. 1994; 269:22137–44. [PubMed: 8071338]
203. Xuan JA, et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. *Cancer Res*. 2006; 66 :3611–9. [PubMed: 16585186]
204. Sun J, Pons J, Craik CS. Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. *Biochemistry*. 2003; 42:892–900. [PubMed: 12549907]
205. Lazarus RA, Olivero AG, Eigenbrot C, Kirchhofer D. Inhibitors of Tissue Factor. Factor VIIa for anticoagulant therapy. *Curr Med Chem*. 2004; 11:2275–90. [PubMed: 15379712]
206. Edwards AM, et al. Too many roads not taken. *Nature*. 470:163–5. [PubMed: 21307913]




**Figure 1. Schematic representation of the serine hydrolase catalytic cycle**

A base-activated serine nucleophile attacks the carbonyl carbon of the scissile bond, forming a covalent intermediate and releasing the first reaction product. A water molecule then hydrolyzes the covalent intermediate to release the second reaction product and regenerate the active enzyme. X= N, O, or S.



**Figure 2. The human serine hydrolases**  
 A dendrogram showing the ~240 predicted human serine hydrolases with branch length depicting sequence relatedness. The metabolic serine hydrolases are colored blue. The remaining enzymes are serine proteases, with chymotrypsin-like enzymes colored black, subtilisin-like enzymes colored red, and other, smaller serine protease clans colored green.









**Figure 3. Overview of the current pharmacological toolkit for serine hydrolases**  
The electrophilic moieties of each compound, if applicable, are colored red.













Table 1

Human serine hydrolase inhibitors approved for clinical use.

| Target | Compound               | Structure   | Company              | Ref(s) | Indication                        |
|--------|------------------------|---|----------------------|--------|-----------------------------------|
| ACHE   | Rivastigmine (Exelon)  |    | Novartis             | 29     | Alzheimer's - associated dementia |
|        | Donepezil (Aricept)    |    | Eisai                | 69     |                                   |
|        | Galantamine (Razadyne) |    | Ortho-McNeil Janssen | 72     |                                   |
|        | Tacrine (Cognex)       |    | Shionogi             | 66     |                                   |
| DPP4   | Sitagliptin (Januvia)  |   | Merck                | 93     | Type II diabetes                  |
|        | Saxagliptin (Onglyza)  |  | Bristol Myers Squibb | 92     |                                   |

| Target                      | Compound                       | Structure   | Company                           | Ref(s) | Indication |
|-----------------------------|--------------------------------|---|-----------------------------------|--------|------------|
|                             | Linagliptin (Tradjenta)        |     | Boehringer Ingelheim              | 94     |            |
|                             | Vildagliptin * (Zomerlis)      |    | Novartis                          | 31     |            |
|                             | Alogliptin * (Nesina)          |    | Takeda                            | 86     |            |
| Pancreatic/ gastric lipases | Orlistat (Xenical; Alli)       |     | Roche; GlaxoSmithKline            | 19, 32 | Obesity    |
|                             | Dabigatran etexilate (Pradaxa) |    | Boehringer Ingelheim              | 46, 47 |            |
| Thrombin                    | Argatroban (Novastan)          |  | GlaxoSmithKline Mitsubishi Pharma | 42     | Thrombosis |








| Target                    | Compound              | Structure  | Company | Ref(s) | Indication          |
|---------------------------|-----------------------|--|---------|--------|---------------------|
| Factor Xa                 | Rivaroxaban (Xarelto) |  | Bayer   | 54, 59 | Thrombosis          |
| Human neutrophil elastase | Sivelestat* (Elaspol) |  | Ono     | 33     | Respiratory disease |




The electrophilic moieties of each compound, if applicable, are colored red. The prodrug portions of dabigatran etexilate are colored blue.

\* Not yet approved in the United States.

Table 2

Examples of serine hydrolase targets and lead inhibitors with potential therapeutic value.










| Target                     | Compound (Company, if applicable)        | Structure  | Ref(s)   | Potential Indication                        | Development Stage   |
|----------------------------|--|--|----------|---|---------------------|
| FAAH                       | OL-135                                   |    | 184      | inflammatory pain; nervous system disorders | preclinical         |
|                            | URB597 (Kadmus Pharmaceuticals)          |    | 77       |   | preclinical         |
|                            | PF-04457845 (Pfizer)                     |    | 13       |   | Phase II            |
| FAP/ dipeptidyl peptidases | PT-100 (Point Therapeutics)              |   | 143, 144 | cancer                                      | Phase III (on hold) |
| LIPG                       | 'Sulfonylfuran urea 1' (GlaxoSmithKline) |    | 121      | cardiovascular disease                      | preclinical         |
| PLA2G7                     | Darapladib (GlaxoSmithKline)             |   | 104      | atherosclerosis                             | Phase III           |
| PRCP                       | 'Compound 80' (Merck)                    |  | 109      | obesity                                     | preclinical         |

| Target | Compound (Company, if applicable) | Structure  | Ref(s) | Potential Indication | Development Stage |
|--------|-----------------------------------|--|--------|----------------------|-------------------|
| PREP   | S 17092                           |  | 127    | cognitive deficits   | preclinical       |
|        | JTP-4819 (Japan Tobacco)          |  | 126    |                      | preclinical       |
| TGH    | GR148672X (GlaxoSmithKline)       |  | 115    | hypertriglyceridemia | preclinical       |

The electrophilic moieties of each compound, if applicable, are colored red.

**Table 3**

Selective inhibitors recently discovered by competitive ABPP

| Target   | Compound | Structure   | Ref. | Potential Indication(s)     |
|----------|----------|---|------|-----------------------------|
| AADA CL1 | AS115    |    | 173  | cancer                      |
|          | JW480    |    | 174  |                             |
| ABHD6    | WWL123   |    | 11   | unknown                     |
| ABHD11   | AA44-2   |    | 14   | unknown                     |
|          | WWL222   |   | 11   |                             |
| APEH     | AA74-1   |  | 14   | unknown                     |
| MGLL     | JZL184   |  | 78   | cancer, pain                |
| PAFAH2   | AA39-2   |  | 14   | unknown                     |
| PME-1    | ABL127   |  | 189  | cancer, Alzheimer's disease |

The electrophilic moieties of each compound are colored red.